| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/14/1994 | CA2211563A1 Anti-inflammatory tolerogenic and immunoinhibiting properties of carbohydrate binding-peptides |
| 04/14/1994 | CA2146572A1 Controlled-ph formulation for intravesicular instillation of tgfpe40 ab |
| 04/14/1994 | CA2146544A1 Ptp 1d: a novel protein tyrosine phosphatase |
| 04/14/1994 | CA2146431A1 Insulin-like peptide |
| 04/14/1994 | CA2146364A1 Therapeutic anti-hiv oligonucleotide and pharmaceutical |
| 04/14/1994 | CA2146324A1 Pharmaceutical composition for the site-specific release of clot-dissolving protein and method for the preparation thereof |
| 04/14/1994 | CA2145847A1 Multimeric polyvalent antithrombotic agents |
| 04/14/1994 | CA2145769A1 Trophic factor having ion channel-inducing activity in neuronal cells |
| 04/14/1994 | CA2145762A1 Pp14-based therapy |
| 04/14/1994 | CA2145757A1 Human neutralizing monoclonal antibodies to human immunodeficiency virus |
| 04/14/1994 | CA2145680A1 Inhibition of cyst formation by cytoskeletal specific drugs |
| 04/14/1994 | CA2145517A1 Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia - tissue factor complex |
| 04/14/1994 | CA2145418A1 Pulmonary delivery of active fragments of parathyroid hormone |
| 04/14/1994 | CA2145391A1 Vaccines and antigenic conjugates |
| 04/14/1994 | CA2144850A1 Anti-inflammatory, tolerogenic and immunostimulatory properties of carbohydrate binding-proteins |
| 04/14/1994 | CA2144059A1 Chitosan matrices for encapsulated cells |
| 04/14/1994 | CA2142974A1 Benzo-fused lactams promote release of growth hormone |
| 04/14/1994 | CA2142724A1 Characterization of a chromosome 11q23 translocation breakpoint associated with acute leukemias |
| 04/14/1994 | CA2124566A1 Allosteric modulators of the nmda receptor |
| 04/14/1994 | CA2124330A1 Novel hirudine variant, process for producing the same, and anticoagulant containing the same as active ingredient |
| 04/13/1994 | EP0592380A1 Ointment for treatment of epithelial lesions |
| 04/13/1994 | EP0592367A2 Phosphono/biaryl substituted dipeptide derivatives |
| 04/13/1994 | EP0592348A1 Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use |
| 04/13/1994 | EP0592242A1 Fibrin sealant compositions and method for utilizing same |
| 04/13/1994 | EP0592230A1 Human monoclonal anti-peptide anti-body and DNA encoding thereof |
| 04/13/1994 | EP0592010A2 Topical compositions containing LYCD and other topically active medicinal ingredients |
| 04/13/1994 | EP0591789A2 Protein forming a water channel and gene therefor |
| 04/13/1994 | EP0591697A2 Cloning and characterization of the growth hormone releasing hormone receptor |
| 04/13/1994 | EP0591605A2 Method for suppressing coloring of human serum albumin |
| 04/13/1994 | EP0591472A1 Expression of enzymatically active recombinant human acetylcholinesterase and uses thereof |
| 04/13/1994 | EP0591462A1 Universal donor cells |
| 04/13/1994 | EP0591458A1 Improved process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates |
| 04/13/1994 | EP0591420A1 A differentiated megakaryocyte line producing novel megakaryocyte differentiation factors |
| 04/13/1994 | EP0591408A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 04/13/1994 | EP0591392A1 Pharmaceutical formulations of osteogenic proteins. |
| 04/13/1994 | EP0591389A1 Dosage form for a delayed drug delivery |
| 04/13/1994 | EP0591385A1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 04/13/1994 | EP0591378A1 Method of preventing and treating chemotherapy-induced alopecia |
| 04/13/1994 | EP0591320A1 Suppressor t-cell hybridoma |
| 04/13/1994 | EP0591316A1 Atp-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
| 04/13/1994 | EP0591281A1 Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them |
| 04/13/1994 | EP0591263A1 Method for inhibiting adhesion of white blood cells to endothelial cells |
| 04/13/1994 | EP0538300B1 O-glycosylated ifn-alpha |
| 04/13/1994 | EP0408677B1 Increasing c1 inhibitor concentrations using interferon gamma alone or in combination with interleukin-6 |
| 04/13/1994 | EP0396616B1 Reduction of side effects of cancer therapy |
| 04/13/1994 | EP0264434B1 Detection of a unique chlamydia strain associated with acute respiratory disease |
| 04/12/1994 | US5302715 For binding to antigens, proteins, polypeptides or other labels for preparation of antibodies useful in immunoassays |
| 04/12/1994 | US5302706 Senescent cell derived inhibitors of DNA synthesis |
| 04/12/1994 | US5302702 Chimeric fibroblast growth factors |
| 04/12/1994 | US5302701 Cell growth promoting activity |
| 04/12/1994 | US5302699 Antitumorigenic protein, method of preparing it and antitumorigenic composition containing the protein as active component |
| 04/12/1994 | US5302697 For controlling secretion of proteins or peptides by genetically engineered saccharomyces culture products |
| 04/12/1994 | US5302582 Enkastins: new glycopeptides which act to inhibit enkephlinase, processes for their preparation, and their use as pharmaceutical products |
| 04/12/1994 | US5302581 Administering with lipids for the treatment of respiratory disease |
| 04/12/1994 | US5302400 Preparation of gastric acid-resistant microspheres containing digestive enzymes and buffered-bile acids |
| 04/12/1994 | US5302397 Polymer-based drug delivery system |
| 04/12/1994 | US5302390 Hybrid proteins of human plasminogen and human t-PA, pharmaceutical compositions and methods of treatment |
| 04/12/1994 | US5302389 Topically administering liposome encapsulated endonuclease |
| 04/12/1994 | US5302384 Administering to treat inflammation |
| 04/12/1994 | CA1328540C Cyclic anticoagulant peptides |
| 04/12/1994 | CA1328402C Somatostatins |
| 04/12/1994 | CA1328401C Diabetic control by combined insulin forms |
| 04/09/1994 | CA2566574A1 Fibrin sealant compositions and method for utilizing same |
| 04/08/1994 | CA2107761A1 Human monoclonal anti-peptide antibody and dna encoding thereof |
| 04/07/1994 | CA2079983A1 Isolated mink growth hormone genes, novel recombinant dna and methods for producing mink growth hormone |
| 04/06/1994 | EP0590531A1 Antithrombin III preparation |
| 04/06/1994 | EP0590530A2 Fusion proteins for prodrug-activation |
| 04/06/1994 | EP0590403A2 Compositions having analgesic action |
| 04/06/1994 | EP0590309A2 Bone-related sulfatase-like protein and process for its production |
| 04/06/1994 | EP0590301A2 Method for protecting plants from disease and infestation by gene insertion, and vectors and plant cells containing said genes |
| 04/06/1994 | EP0590156A1 Novel, physiologically active protein and hemopoietic stem cell growth promoter |
| 04/06/1994 | EP0590152A1 Peptides with tachykinin antagonist activity |
| 04/06/1994 | EP0590138A1 Oral treatment of helicobacter infection |
| 04/06/1994 | EP0590126A1 Polypeptides having kinase activity, their preparation and use |
| 04/06/1994 | EP0590109A1 $i(IN VIVO) BINDING PAIR PRETARGETING |
| 04/06/1994 | EP0590092A1 Nitrosation of homocysteine as a method for treating homocysteinemia |
| 04/06/1994 | EP0590090A1 SELECTIVE INHIBITION OF LEUKEMIC CELL PROLIFERATION BY $i(BCR-ABL) ANTISENSE OLIGONUCLEOTIDES |
| 04/06/1994 | EP0590082A1 Antisense oligonucleotide inhibition of the ras gene |
| 04/06/1994 | EP0590076A1 Production of human hemoglobin in transgenic pigs |
| 04/06/1994 | EP0590071A1 SUBSTANTIALLY PURE RECEPTOR LIKE TGF-$g(b)1 BINDING MOLECULES AND USES THEREOF |
| 04/06/1994 | EP0590070A1 Broad spectrum antimicrobial compounds and methods of use |
| 04/06/1994 | EP0590067A1 Microbially-produced antibody fragments and their conjugates |
| 04/06/1994 | EP0590058A1 Method for making humanized antibodies |
| 04/06/1994 | EP0590055A1 M-protein peptides of influenza virus as antiviral agents |
| 04/06/1994 | EP0590051A1 Intercellular adhesion molecule-3 and its binding ligands |
| 04/06/1994 | EP0590048A1 Therapeutic fragments of von willebrand factor |
| 04/06/1994 | EP0590044A1 Composition and treatment with biologically active peptides having c-terminal substitutions |
| 04/06/1994 | EP0590030A1 A receptor-type tyrosine kinase [human eph/elk-like kinase - hek] and use thereof |
| 04/06/1994 | EP0590015A1 Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer |
| 04/06/1994 | EP0590006A1 Synthetic pulmonary surfactant peptides |
| 04/06/1994 | EP0590003A1 New medicinal use of igf-ii |
| 04/06/1994 | EP0589995A1 Novel polypeptides and their use |
| 04/06/1994 | EP0589993A1 Human p450 iid6 cytochrome-derived peptide fragments, anti peptide fragment antibodies, and applications thereof in the diagnosis of autoimmune hepatitis |
| 04/06/1994 | EP0589989A1 USE OF $g(b)-CELL TROPIN (ACTH 22-39) ANTAGONISTS IN THE TREATMENT OF HYPERINSULINAEMIA AND ASSOCIATED DISEASES |
| 04/06/1994 | EP0589982A1 Monoclonal antibodies against human tnf-binding protein i (tnf-bp i) |
| 04/06/1994 | EP0589961A1 Assay systems for neurotrophin activity |
| 04/06/1994 | EP0589955A1 Medicinal use of jacaline and fragments thereof, in particular for treating hiv-related diseases |
| 04/06/1994 | EP0589951A1 Modified sialyl lewis?x compounds |
| 04/06/1994 | EP0589943A1 Mycobacterium proteins and applications |
| 04/06/1994 | EP0589937A1 USE OF 4-(4-CHLOROPHENYL-SULPHONYLCARBAMOYL) BENZOYL-L-VALYL-L-PROLINE 1($i(RS))-(1-TRIFLUOROACETYL-2-METHYLPROPYL) AMIDE IN THE TREATMENT OF VASCULAR DISEASES |